Literature DB >> 17172368

Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment.

Manuel Calvopina1, Eduardo A Gomez, Herbert Sindermann, Philip J Cooper, Yoshihisa Hashiguchi.   

Abstract

A 35-year-old man with a 19-year history of slowly evolving diffuse cutaneous leishmaniasis was treated with oral miltefosine, 50 mg three times a day. The patient responded after four months of miltefosine treatment with clearance of all nodular lesions and plaques from the entire body surface and had negative slit-skin smears and cultures for Leishmania. However, two months after stopping miltefosine, skin lesions reappeared and parasites were observed in samples. The relapsed lesions did not respond to an additional two-month course of miltefosine. No laboratory or clinical adverse events to miltefosine were observed. Parasites from skin lesions were cultured and identified as Leishmania (Leishmania) mexicana by isoenzyme electrophoresis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17172368

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  15 in total

Review 1.  Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.

Authors:  Begoña Monge-Maillo; Rogelio López-Vélez
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

2.  Cutaneous leishmaniasis after travel to Cyprus and successful treatment with miltefosine.

Authors:  Wolfgang Poeppl; Julia Walochnik; Tom Pustelnik; Herbert Auer; Gerhard Mooseder
Journal:  Am J Trop Med Hyg       Date:  2011-04       Impact factor: 2.345

3.  Case report: Transient success using prolonged treatment with miltefosine for a patient with diffuse cutaneous leishmaniasis infected with Leishmania mexicana mexicana.

Authors:  Alejandro Ordaz-Farias; Fania Z Muñoz-Garza; Farah K Sevilla-Gonzalez; Ana Arana-Guajardo; Jorge Ocampo-Candiani; Nancy Treviño-Garza; Ingeborg Becker; Adrian Camacho-Ortiz
Journal:  Am J Trop Med Hyg       Date:  2012-12-12       Impact factor: 2.345

4.  Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern.

Authors:  Jyotsna Mishra; Rentala Madhubala; Sarman Singh
Journal:  Parasitol Res       Date:  2012-12-18       Impact factor: 2.289

5.  Activity of hydroxyurea against Leishmania mexicana.

Authors:  Hugo Martinez-Rojano; Javier Mancilla-Ramirez; Laura Quiñonez-Diaz; Norma Galindo-Sevilla
Journal:  Antimicrob Agents Chemother       Date:  2008-08-11       Impact factor: 5.191

6.  In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasites.

Authors:  Rubén E Varela-M; Janny A Villa-Pulgarin; Edward Yepes; Ingrid Müller; Manuel Modolell; Diana L Muñoz; Sara M Robledo; Carlos E Muskus; Julio López-Abán; Antonio Muro; Iván D Vélez; Faustino Mollinedo
Journal:  PLoS Negl Trop Dis       Date:  2012-04-10

7.  Cutaneous Leishmaniasis Treated with Miltefosine: A Case Series of 10 Paediatric Patients.

Authors:  Ayelet Ollech; Michal Solomon; Amir Horev; Shiran Reiss-Huss; Dan Ben-Amitai; Alex Zvulunov; Rivka Friedland; Vered Atar-Snir; Vered Molho-Pessach; Aviv Barzilai; Shoshana Greenberger
Journal:  Acta Derm Venereol       Date:  2020-10-19       Impact factor: 3.875

8.  An Atypical Case of Autochthonous Cutaneous Leishmaniasis Associated with Naturally Infected Phlebotomine Sand Flies in Texas, United States.

Authors:  Evan J Kipp; Marcos de Almeida; Paula L Marcet; Richard S Bradbury; Theresa K Benedict; Wuling Lin; Ellen M Dotson; Melinda Hergert
Journal:  Am J Trop Med Hyg       Date:  2020-10       Impact factor: 3.707

9.  Case Report: Successful Treatment with Miltefosine of Severe New World Mucosal Leishmaniasis Caused by Leishmania guyanensis.

Authors:  Manuel Calvopina; Sara Jijon; Esteban Serrano; Hirotomo Kato
Journal:  Am J Trop Med Hyg       Date:  2020-06-04       Impact factor: 2.345

10.  A Luciferase-Expressing Leishmania braziliensis Line That Leads to Sustained Skin Lesions in BALB/c Mice and Allows Monitoring of Miltefosine Treatment Outcome.

Authors:  Adriano C Coelho; Jordana C Oliveira; Caroline R Espada; Juliana Q Reimão; Cristiana T Trinconi; Silvia R B Uliana
Journal:  PLoS Negl Trop Dis       Date:  2016-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.